Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Author
Karim Fizazi
Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France
info_outline
Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschaebitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Neeraj Agarwal
Full text
Authors
Karim Fizazi
Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France
info_outline
Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschaebitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Neeraj Agarwal
Organizations
Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Chiba, Japan, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, PUCRS School of Medicine, Porto Alegre, Brazil, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, National Cancer Center, Goyang-Si, South Korea, Auckland City Hospital and University of Auckland, Auckland, New Zealand, Clinique Victor Hugo Centre Jean Bernard, Le Mans, France, School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, Carolina Urologic Research Center, Myrtle Beach, SC, Arizona Urology Specialists, Tucson, AZ, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany, Akershus University Hospital (Ahus), Lørenskog, Norway, Pfizer Inc., La Jolla, CA, Pfizer Inc., Collegeville, PA, Pfizer Inc., Durham, NC, Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT
Abstract Disclosures
Research Funding
Pharmaceutical/Biotech Company
Pfizer Inc., Astellas Pharma Inc. provided enzalutamide
Background:
TALAPRO-2 is the first phase 3 study to combine the poly(ADP-ribose) polymerase inhibitor TALA with the androgen receptor inhibitor ENZA in pts with 1L mCRPC unselected (Cohort 1—previously reported) or selected (Cohort 2) for HRR gene alterations. Here, we report results of the prespecified, independently powered analysis of pts with mCRPC with HRR gene alterations from Cohorts 1 and 2.
Methods:
From February 2019 to January 2022, 399 pts (169 from Cohort 1) were randomized 1:1 to receive TALA 0.5 mg or PBO (all received ENZA 160 mg) once daily. Randomization was stratified by prior abiraterone or docetaxel for castration-sensitive PC (yes vs no). Key eligibility criteria: mildly or asymptomatic mCRPC with disease progression at study entry, HRR-deficient status prospectively confirmed by tumor tissue and/or ctDNA testing (genes tested: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C), ECOG PS ≤1, ongoing androgen deprivation therapy, no prior life-prolonging therapy for CRPC. Primary endpoint: radiographic progression-free survival (rPFS) by BICR per RECIST 1.1 and PCWG3.
Results:
200 pts received TALA + ENZA and 199 PBO + ENZA. TALA + ENZA significantly improved rPFS by BICR (HR 0.45; 95% CI, 0.33–0.61; 2-sided P< 0.001; median PFS not reached vs 13.8 months). The HR for rPFS by BICR was 0.20 (95% CI, 0.11–0.36; P< 0.001) for the BRCA1/2 subgroup (n=155) and 0.68 (95% CI, 0.46–1.02; P = 0.06) in those without a BRCA1/2 alteration (n=240). The first interim analysis of OS was immature: 21.5% (TALA + ENZA) and 26.6% (PBO + ENZA) pts had died; HR 0.69 (95% CI, 0.46–1.03; P = 0.07). TALA + ENZA delayed time to PSA progression, cytotoxic chemotherapy, and antineoplastic therapy, and improved ORR, PSA response, and investigator-assessed PFS2. Grade (G) 3–4 treatment-emergent adverse events (TEAEs) were reported for 66.2% (TALA + ENZA) vs 37.2% (PBO + ENZA). There were more G≥3 hematologic TEAEs (anemia, neutropenia, thrombocytopenia, and leukopenia) with TALA + ENZA vs PBO + ENZA. TEAEs led to discontinuation of TALA in 10.1% vs PBO in 7.0%; discontinuation rates of ENZA were 7.6% (TALA + ENZA) vs 7.0% (PBO + ENZA). Time to definitive clinically meaningful deterioration in global health status/quality of life (GHS/QoL) was significantly longer with TALA + ENZA vs PBO + ENZA (HR 0.69; 95% CI, 0.49–0.97; P = 0.03; median 27.1 vs 19.3 months).
Conclusions:
TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in rPFS over standard of care ENZA as 1L treatment for pts with mCRPC and HRR gene alterations, while delaying time to definitive clinically meaningful deterioration in GHS/QoL. Toxicity was generally manageable and consistent with known safety profiles of TALA and ENZA. Clinical trial information: NCT03395197.
1 clinical trial
39 organizations
1 product
5 drugs
14 targets
Organization
University of Paris-SaclayOrganization
Vall d’Hebron University Hospital/VHIOOrganization
Barcelona, SpainOrganization
Porto Alegre, BrazilOrganization
Meldola, ItalyOrganization
Goyang-Si, South KoreaOrganization
Auckland, New ZealandOrganization
Le Mans, FranceOrganization
University of GlasgowOrganization
Glasgow, United KingdomOrganization
Myrtle Beach, SCOrganization
Tucson, AZOrganization
Heidelberg University HospitalOrganization
Akershus University Hospital (Ahus)Organization
Pfizer Inc.Organization
Huntsman Cancer Institute (NCI-CCC)Organization
Salt Lake City, UTOrganization
Institut Gustave RoussyOrganization
Villejuif, FranceOrganization
Melbourne, AustraliaOrganization
Chiba, JapanOrganization
Vall d’Hebron Institute of Oncology (VHIO)Organization
PUCRS School of MedicineOrganization
Clinique Victor Hugo Centre Jean BernardOrganization
School of Cancer SciencesOrganization
Beatson West of Scotland Cancer CentreOrganization
Carolina Urologic Research CenterOrganization
Arizona Urology SpecialistsOrganization
National Center for Tumor Diseases (NCT)Organization
Heidelberg, GermanyOrganization
Lørenskog, NorwayOrganization
La Jolla, CAOrganization
Collegeville, PAOrganization
Durham, NCOrganization
University of UtahProduct
TalazoparibClinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCERStatus: Active (not recruiting), Estimated PCD: 2022-10-03
Drug
enzalutamideDrug
talazoparibTarget
ATMTarget
CDK12Target
CHEK2Target
MRE11ATarget
BRCA2Target
RAD51CTarget
androgen receptorTarget
FANCATarget
NBNTarget
PALB2Target
MLH1Target
BRCA1Drug
pboDrug
abirateroneDrug
docetaxel